OncoLab Co., Ltd.

Based in South Korea, OncoLab is a deep tech biotechnology firm specializing in innovative immune-oncology treatments. The company focuses on developing advanced therapeutics for hard-to-treat cancers, offering solutions that enhance drug delivery and efficacy. OncoLab Co. , Ltd.

is a biotechnology company founded in 2024, located in Cheongju, South Korea. It specializes in immune-oncology solutions. The company has engaged in 1 deal, with its most recent funding round occurring in November 2025, where it raised KRW 1 billion in pre-Series A funding from FuturePlay, bringing the total amount raised to KRW 1 billion. The founder's history and previous ventures are not disclosed.

OncoLab's primary offering is the ANGel platform, a next-generation immune-oncology treatment system designed for superior drug delivery, efficacy, and sustainability. This platform is engineered to develop therapeutics targeting hard-to-treat cancers, including triple-negative breast cancer and various solid tumors. The ANGel technology utilizes antibody-conjugated nanogels, which enhance the precision and effectiveness of cancer therapies. The company aims to address significant unmet needs in oncology by providing innovative solutions to healthcare providers and ultimately improving patient outcomes.

OncoLab serves a diverse clientele, including hospitals, cancer treatment centers, and research institutions across North America and Asia, where its products are actively deployed in clinical settings. Revenue generation for OncoLab is primarily structured through partnerships and collaborations with healthcare institutions and research organizations. The company engages in B2B transactions, providing its ANGel platform and associated therapeutics to oncology specialists and healthcare providers. Typical agreements may involve licensing fees for the use of their patented technologies, along with revenue-sharing models based on the commercialization of therapies developed using the platform.

OncoLab’s flagship product, the antibody-conjugated nanogel, serves as a cornerstone for its revenue strategy, enabling the company to forge robust relationships with pharmaceutical companies and healthcare providers in the oncology sector. OncoLab plans to utilize the KRW 1 billion raised in November 2025 to conduct global clinical trials and expand its product scope. This funding will support the development of upcoming therapeutics aimed at enhancing cancer treatment efficacy. The company is also targeting expansion into new geographic markets, including further penetration in North America and Asia by 2026.